Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 5/2016

01-09-2016 | Highlights

News and views

Author: Sander M. Houten

Published in: Journal of Inherited Metabolic Disease | Issue 5/2016

Login to get access

Excerpt

Human genetics has mostly focused on variants that cause or predispose to disease. Identifying genetic variants that keep humans healthy is an equally attractive approach to identify novel drug targets. Two recent studies have highlighted that such endeavors are worthwhile. In a study published in Cell, Erikson et al. performed whole genome sequencing in a cohort of individuals with a healthy aging phenotype defined as >80 years old without chronic diseases or chronic medications, also known as the Wellderly study [1]. The investigators found that healthy aging is associated with reduced genetic susceptibility to Alzheimer (depletion of APOE-ε4 alleles) and coronary artery disease. They also identified one gene of major interest, COL25A1, which contained ultra-rare coding variants in multiple Wellderly individuals. The investigators speculate that mutations in COL25A1 may disrupt Alzheimer disease pathogenesis, which is consistent with their overall finding that healthy aging is associated with genetic resistance to cognitive decline. …
Literature
1.
go back to reference Erikson GA, Bodian DL, Rueda M, Molparia B, Scott ER, Scott-Van Zeeland AA, Topol SE, Wineinger NE, Niederhuber JE, Topol EJ, Torkamani A (2016) Whole-genome sequencing of a healthy aging cohort. Cell 165:1002–1011CrossRefPubMed Erikson GA, Bodian DL, Rueda M, Molparia B, Scott ER, Scott-Van Zeeland AA, Topol SE, Wineinger NE, Niederhuber JE, Topol EJ, Torkamani A (2016) Whole-genome sequencing of a healthy aging cohort. Cell 165:1002–1011CrossRefPubMed
2.
go back to reference Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, Zhou H, Tian L, Prakash O, Lemire M, Sleiman P, Cheng WY, Chen W, Shah H, Shen Y, Fromer M, Omberg L, Deardorff MA, Zackai E, Bobe JR, Levin E, Hudson TJ, Groop L, Wang J, Hakonarson H, Wojcicki A, Diaz GA, Edelmann L, Schadt EE, Friend SH (2016) Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nature biotechnology 34:531–538CrossRefPubMed Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, Zhou H, Tian L, Prakash O, Lemire M, Sleiman P, Cheng WY, Chen W, Shah H, Shen Y, Fromer M, Omberg L, Deardorff MA, Zackai E, Bobe JR, Levin E, Hudson TJ, Groop L, Wang J, Hakonarson H, Wojcicki A, Diaz GA, Edelmann L, Schadt EE, Friend SH (2016) Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nature biotechnology 34:531–538CrossRefPubMed
3.
go back to reference Gao F, Shen XZ, Jiang F, Wu Y, Han C (2016) DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol. doi:10.1038/nbt.3547 Gao F, Shen XZ, Jiang F, Wu Y, Han C (2016) DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol. doi:10.​1038/​nbt.​3547
4.
go back to reference Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regev A, Lander ES, Koonin EV, Zhang F (2016) C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. doi:10.1126/science.aaf5573 Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regev A, Lander ES, Koonin EV, Zhang F (2016) C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. doi:10.​1126/​science.​aaf5573
Metadata
Title
News and views
Author
Sander M. Houten
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 5/2016
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9957-6

Other articles of this Issue 5/2016

Journal of Inherited Metabolic Disease 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.